What is the current Price Target for the Seres Therapeutics Inc stock?

The average Seres Therapeutics Inc target price is $3.25. This is 467.79% higher than the current stock price. The highest price target is 1,647.03%, the lowest is 31.03%. 4 Analysts have issued a price target Seres Therapeutics Inc 2026 .

How high will the Seres Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Seres Therapeutics Inc stock will rise. The performance of stocks, including the Seres Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Seres Therapeutics Inc stock today?

The performance of Seres Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Seres Therapeutics Inc stock fall?

The decline in Seres Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Seres Therapeutics Inc Forecast, price target & analysts

$0.57

10.56% yesterday

Nasdaq, Apr 07, 10:08 pm CET

ISIN

US81750R1023

Symbol

MCRB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Seres Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Seres Therapeutics Inc Classifications & Recommendation:

Buy

57%

Hold

14%

Sell

29%

Seres Therapeutics Inc Price Target

Target Price	$3.25
Price	$0.57
Potential	467.79% register free of charge
Number of Estimates	4

	4 Analysts have issued a price target Seres Therapeutics Inc 2026 . The average Seres Therapeutics Inc target price is $3.25. This is 467.79% register free of charge higher than the current stock price. The highest price target is $10.00 1,647.03% register free of charge , the lowest is $0.75 31.03% register free of charge .
	A rating was issued by 7 analysts: 4 Analysts recommend Seres Therapeutics Inc to buy, 1 to hold and 2 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Seres Therapeutics Inc stock has an average upside potential 2026 of 467.79% register free of charge . Most analysts recommend the Seres Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-0.94	-0.16
	5.62%	82.98%
P/E		negative
EV/Sales		4.86

6 Analysts have issued a Seres Therapeutics Inc forecast for earnings per share. The average Seres Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-0.94	5.62%
2025	$-0.16 82.98% Unlock
2026	$-0.24 50.00% Unlock
2027	$0.05 120.83% Unlock
2028	$-0.50 1,100.00% Unlock
2029	$-0.50 0.00% Unlock

Current	-0.60	29.41%
2025	-3.59 498.33% Unlock
2026	-2.37 33.98% Unlock
2027	12.32 619.83% Unlock
2028	-1.14 109.25% Unlock
2029	-1.14 0.00% Unlock

Seres Therapeutics Inc...

Current Seres Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Chardan Capital	Locked ➜ Locked	Locked	Mar 20 2025
Goldman Sachs	Locked ➜ Locked	Locked	Mar 14 2025
Canaccord Genuity	Locked ➜ Locked	Locked	Nov 14 2024
Chardan Capital	Locked ➜ Locked	Locked	Nov 13 2024
JP Morgan	Locked ➜ Locked	Locked	Oct 24 2024
Canaccord Genuity	Locked ➜ Locked	Locked	Sep 13 2024

Analyst Rating	Date
Locked Chardan Capital: Locked ➜ Locked	Mar 20 2025
Locked Goldman Sachs: Locked ➜ Locked	Mar 14 2025
Locked Canaccord Genuity: Locked ➜ Locked	Nov 14 2024
Locked Chardan Capital: Locked ➜ Locked	Nov 13 2024
Locked JP Morgan: Locked ➜ Locked	Oct 24 2024
Locked Canaccord Genuity: Locked ➜ Locked	Sep 13 2024

Discover more stocks with a high price target

MongoDB 96.77%

Coinbase Global, Inc. 95.22%

BioNTech SE - ADR 59.48%

Snowflake 58.39%

Alibaba Group Holding Ltd 58.36%

PayPal 58.24%

NIO ADR 57.59%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now